Dzhumber Ugrekhelidze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dzhumber Ugrekhelidze has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- V. A. Krylov
Pirogov Russian National Research Medical University
2 shared publications - Alla Sergeevna Salasyuk
Volgograd State Medical University
1 shared publication - Andrey Kulikov
Department of Organization of Medical Provision and Pharmacoeconomics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia
1 shared publication - Array V. Rudakova
Federal Scientific and Clinical Center for Infectious Diseases of the Federal Medical and Biological Agency of Russia; Saint Petersburg State University of Chemistry and Pharmacy, Ministry of Health of the Russian Federation
1 shared publication Burcu Akyol
Patient Access and Corporate Affairs, MSD
1 shared publication- Claudine Bommer
External Affairs and Market Access, MSD
1 shared publication
Latest Publications
- Open Access
- 7 August 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2121-2134
Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland
1. Head and neck squamous cell carcinoma (HNSCC) is a group of malignancies including cancers of the oral cavity, oropharynx, hypopharynx, and larynx.1 Worldwide, HNSCC is the seventh most common c...
- 7 August 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2121-2134
Open AccessCost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland
1. Head and neck squamous cell carcinoma (HNSCC) is a group of malignancies including cancers of the oral cavity, oropharynx, hypopharynx, and larynx.1 Worldwide, HNSCC is the seventh most common c...
- Open Access
- 27 September 2020
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 27-33
Economic consequences of mandatory price re-registration for medicines from the high-cost nosology program
The Government Decree, approved in December 2019, required registration certificates holders of reference drugs, included in the essential drug list (EDL), submit applications for mandatory price re-registration. Drugs included in the high-cost nosology list (high-cost list) must be included in the EDL.Objective: to assess the budget impact of price re-registration for high-cost list drugs.Material and methods. The comparing economic analysis of high-cost nosology program before and after price re-registration based on the Government Decree N 1683 (effective from 16.12.2019). 125 reference stock keeping units (SKUs), included in the high-cost list, were evaluated.Results. The analysis showed, that after re-registration the prices of 66 SKUs will remain the same. The prices of 43 reference SKUs will be reduced after setting a single maximum selling price («equalization»). Prices for 16 SKUs will be reduced due to lower registered prices in the reference countries. Considering the contracts executed in 20192020, the budget of the high-cost program is up to 74.430 billion rubles, and after re-registration it will be equal to 64.162 billion rubles, so the savings will amount 10.267 billion (13.8 %). The main drivers of re-registration prices savings are: Advagraf (1.175 billion rubles), Elizaria (2.083 billion rubles) and Revlimid (2.247 billion rubles). Separately, we analyzed the consequences ofprices re-registration in the V-thgroup ofhigh-cost list, which are provided topatients with malignant neoplasms of lymphoid, hematopoietic and related tissues. It was calculated, that in 2019 the contracts for V-th group of high-cost list were signed for 19.217 billion rubles, and after the price re-registration for the purchase of the same number of drugs 16.762 billion rubles will be spent, so the savings from the price re-registration will amount to 2.455 billion rubles (12.8 %), among which 2.247 billion rubles will be provided by price re-registration of Revlimid.Conclusions. The pricing policy implemented in the Russian Federation is aimed at increasing the availability of highly effective medical care to the population of the Russian Federation and significantly reduces the burden on the budget of the healthcare system.
- 27 September 2020
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 27-33
Open AccessEconomic consequences of mandatory price re-registration for medicines from the high-cost nosology program
The Government Decree, approved in December 2019, required registration certificates holders of reference drugs, included in the essential drug list (EDL), submit applications for mandatory price re-registration. Drugs included in the high-cost nosology list (high-cost list) must be included in the EDL.Objective: to assess the budget impact of price re-registration for high-cost list drugs.Material and methods. The comparing economic analysis of high-cost nosology program before and after price re-registration based on the Government Decree N 1683 (effective from 16.12.2019). 125 reference stock keeping units (SKUs), included in the high-cost list, were evaluated.Results. The analysis showed, that after re-registration the prices of 66 SKUs will remain the same. The prices of 43 reference SKUs will be reduced after setting a single maximum selling price («equalization»). Prices for 16 SKUs will be reduced due to lower registered prices in the reference countries. Considering the contracts executed in 20192020, the budget of the high-cost program is up to 74.430 billion rubles, and after re-registration it will be equal to 64.162 billion rubles, so the savings will amount 10.267 billion (13.8 %). The main drivers of re-registration prices savings are: Advagraf (1.175 billion rubles), Elizaria (2.083 billion rubles) and Revlimid (2.247 billion rubles). Separately, we analyzed the consequences ofprices re-registration in the V-thgroup ofhigh-cost list, which are provided topatients with malignant neoplasms of lymphoid, hematopoietic and related tissues. It was calculated, that in 2019 the contracts for V-th group of high-cost list were signed for 19.217 billion rubles, and after the price re-registration for the purchase of the same number of drugs 16.762 billion rubles will be spent, so the savings from the price re-registration will amount to 2.455 billion rubles (12.8 %), among which 2.247 billion rubles will be provided by price re-registration of Revlimid.Conclusions. The pricing policy implemented in the Russian Federation is aimed at increasing the availability of highly effective medical care to the population of the Russian Federation and significantly reduces the burden on the budget of the healthcare system.
- Open Access
- 15 December 2016
- Published by Moscow Pharmaceutical Society in Pharmacoeconomics: theory and practice
- Vol. 4 (4) , 60-108
Analysis of pharmacoeconomic and clinical economic studies published in the scientific electronic library “eLIBRARY.RU” (RSCI) for the period from 2005 to 2015
- 15 December 2016
- Published by Moscow Pharmaceutical Society in Pharmacoeconomics: theory and practice
- Vol. 4 (4) , 60-108
Open AccessAnalysis of pharmacoeconomic and clinical economic studies published in the scientific electronic library “eLIBRARY.RU” (RSCI) for the period from 2005 to 2015